or Try an Advanced Search...

    Technical Analysis for SNGX - Soligenix, Inc.

    Grade Last Price % Change Price Change
    F 2.47 -4.26% -0.11
    SNGX closed down 4.26 percent on Monday, July 1, 2024, on 70 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical SNGX trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -4.26%
    Volume Surge Other -4.26%
    New 52 Week Low Weakness -4.26%
    Older End-of-Day Signals for SNGX ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 9 hours ago
    Down 3% about 9 hours ago
    Up 3% about 9 hours ago
    Fell Below Previous Day's Low about 9 hours ago
    Down 2 % about 9 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    SNGX Chart by TradingView
    Basic chart:

    Profile

    Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ' (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Cancer Treatment Gastrointestinal Radiation Therapeutic Products Toxins Proteins Biodefense Biological Warfare Gastrointestinal Disease Lectins Biotherapeutic Products

    Is SNGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 14 A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
    Jun 14 SNGX: Valuation Change Based on Reverse Split…
    Jun 7 Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Jun 5 Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
    May 31 Soligenix to effect 1-for-16 reverse stock split
    May 31 Soligenix Announces Reverse Stock Split
    May 29 Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
    May 24 Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
    May 16 Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
    May 14 SNGX: Second Confirmatory Phase 3 Trial of HyBryte™ in CTCL to Initiate Before End of 2024…
    See more SNGX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 32.0
    52 Week Low 2.442
    Average Volume 69,495
    200-Day Moving Average 8.51
    50-Day Moving Average 5.20
    20-Day Moving Average 3.66
    10-Day Moving Average 3.17
    Average True Range 0.55
    RSI (14) 24.24
    ADX 27.86
    +DI 17.59
    -DI 28.01
    Chandelier Exit (Long, 3 ATRs) 4.27
    Chandelier Exit (Short, 3 ATRs) 4.09
    Upper Bollinger Bands 5.22
    Lower Bollinger Band 2.11
    Percent B (%b) 0.12
    BandWidth 85.03
    MACD Line -0.80
    MACD Signal Line -0.75
    MACD Histogram -0.0523
    Fundamentals Value
    Market Cap 26 Million
    Num Shares 10.5 Million
    EPS -1.46
    Price-to-Earnings (P/E) Ratio -1.69
    Price-to-Sales 7.44
    Price-to-Book 1.65
    PEG Ratio -1.52
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.80
    Resistance 3 (R3) 2.82 2.74 2.74
    Resistance 2 (R2) 2.74 2.66 2.73 2.72
    Resistance 1 (R1) 2.61 2.61 2.57 2.58 2.71
    Pivot Point 2.52 2.52 2.50 2.51 2.52
    Support 1 (S1) 2.39 2.44 2.35 2.36 2.23
    Support 2 (S2) 2.31 2.39 2.29 2.22
    Support 3 (S3) 2.17 2.31 2.20
    Support 4 (S4) 2.14